Targeted therapy for neuro-oncology: reviewing the menu

Drug Discovery Today

Volumn 14, Issue 3-4, 2009, Pages 185-191

  Lampson, Lois A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; TEMOZOLOMIDE; TRASTUZUMAB;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CANCER THERAPY; DRUG MECHANISM; GLIOBLASTOMA; IMMUNE RESPONSE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 58849163070     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.11.003     Document Type: Review

References (58)

1. Reichert J.M., and Wenger J.B. Development trends for new cancer therapeutics and vaccines. Drug Discov. Today 13 (2008) 30-37
2. O'Hare T., et al. Targeted CML therapy: controlling drug resistance, seeking cure. Curr. Opin. Genet. Dev. 16 (2006) 92-99
3. Ritchie E., and Nichols G. Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy. Curr. Cancer Drug Targets 6 (2006) 645-657
4. Walz C., and Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit. Rev. Oncol. Hematol. 57 (2006) 145-164
5. Bria E., et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res. Treat. 109 (2008) 231-239
6. Wieduwilt M.J., and Moasser M.M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol. Life Sci. 65 (2008) 1566-1584
7. Cardones A.R., and Banez L.L. VEGF inhibitors in cancer therapy. Curr. Pharm. Des. 12 (2006) 387-394
8. Scott L.J. Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs 67 (2007) 1793-1799
9. Mellinghoff I.K., and Sawyers C.L. The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics 3 (2002) 603-623
10. Perez E.A., et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin. Proc. 83 (2008) 679-686
11. Brandes A.A., et al. Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin. Cancer Res. 14 (2008) 957-960
12. Hegi M.E., et al. Brain tumors: molecular biology and targeted therapies. Ann. Oncol. 17 Suppl. 10 (2006) x191-x197
13. Jansen M., et al. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res. Rev. 45 (2004) 143-163
14. Sathornsumetee S., et al. Molecularly targeted therapy for malignant glioma. Cancer 110 (2007) 13-24
15. Dehdashti A.R., et al. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg. Focus 20 (2006) E6
16. Newlands E.S., et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev. 23 (1997) 35-61
17. Payne M.J., et al. Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. Crit. Rev. Oncol. Hematol. 53 (2005) 241-252
18. Barone G., et al. Role of temozolomide in pediatric brain tumors. Childs Nerv. Syst. 22 (2006) 652-661
19. Ohgaki H., and Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. Neuropathol. Exp. Neurol. 64 (2005) 479-489
20. Douglas J.G., et al. [F-18] fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int. J. Radiat. Oncol. Biol. Phys. 64 (2006) 886-891
21. Kaal E.C., and Vecht C.J. CNS complications of breast cancer: current and emerging treatment options. CNS Drugs 21 (2007) 559-579
22. Patel R.R., and Mehta M.P. Targeted therapy for brain metastases: improving the therapeutic ratio. Clin. Cancer Res. 13 (2007) 1675-1683
23. van den Bent M.J. The role of chemotherapy in brain metastases. Eur. J. Cancer 39 (2003) 2114-2120
24. Vogelbaum M.A., et al. S100beta as a predictor of brain metastases: brain versus cerebrovascular damage. Cancer 104 (2005) 817-824
25. Claes A., et al. Diffuse glioma growth: a guerilla war. Acta Neuropathol. 114 (2007) 443-458
26. In: Kleihues P., and Cavenee W.K. (Eds). Pathology and Genetics of Tumours of the Nervous System (1997), International Agency for Research on Cancer, Lyon
27. Mitchell P., et al. Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurol. 4 (2005) 413-422
28. Sawrie S.M., et al. Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int. J. Radiat. Oncol. Biol. Phys. 70 (2008) 181-186
29. Aydin H., et al. Patterns of failure following CT-based 3-D irradiation for malignant glioma. Strahlenther. Onkol. 177 (2001) 424-431
30. Nakagawa K., et al. High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 40 (1998) 1141-1149
31. Chang J.E., et al. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin. Adv. Hematol. Oncol. 5 (2007) 894-902 907-917
32. Giese A., et al. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J. Neurooncol. 66 (2004) 351-360
33. Park I., et al. Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. Int. J. Radiat. Oncol. Biol. Phys. 69 (2007) 381-389
34. Garside R., et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol. Assess. 11 (2007) iii-iv, ix-221
35. Chow S.C., and Chang M. Adaptive design methods in clinical trials - a review. Orphanet. J. Rare Dis. 3 (2008) 11
36. Lin N.U., et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 26 (2008) 1993-1999
37. Jin L., et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol. Cancer Ther. 7 (2008) 48-58
38. Wanami L.S., et al. Vascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: implications for tumor progression. Exp. Cell Res. 314 (2008) 2448-2453
39. Lampson L.A. Molecular bases of neuronal individuality: lessons from anatomical and biochemical studies with monoclonal antibodies. In: Kennett R.H., et al. (Ed). Monoclonal Antibodies and Functional Cell Lines: Progress and Applications (1984), Plenum Press 153-189
40. McCluskey L.P., and Lampson L.A. Local immune regulation in the central nervous system by substance P vs. glutamate. J. Neuroimmunol. 116 (2001) 136-146
41. Huang Y., et al. Macrophage-mediated bystander effect triggered by tumor cell apoptosis. Mol. Ther. 15 (2007) 524-533
42. Muller A.J., and Scherle P.A. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat. Rev. Cancer 6 (2006) 613-625
43. Wirenfeldt M., et al. Reactive microgliosis engages distinct responses by microglial subpopulations after minor central nervous system injury. J. Neurosci. Res. 82 (2005) 507-514
44. Lumniczky K., and Safrany G. Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect. Pathol. Oncol. Res. 12 (2006) 118-124
45. Mothersill C., and Seymour C.B. Targeted radiotherapy: is the "Holy Grail" in sight?. J. Nucl. Med. 47 (2006) 899-900
46. Chen Y., et al. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol. Interv. 7 (2007) 147-156
47. Claes A., et al. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol. Cancer Ther. 7 (2008) 71-78
48. Norden A.D., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70 (2008) 779-787
49. Okaji Y., et al. Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur. J. Cancer 44 (2008) 383-390
50. Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer 45 Suppl. 2 (2004) S253-S257
51. Church D.N., et al. HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab - a case report. J. Neurooncol. 79 (2006) 289-292
52. Zamecnik J. The extracellular space and matrix of gliomas. Acta Neuropathol. 110 5 (2005) 435-442
53. Jackman D.M., et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J. Clin. Oncol. 24 (2006) 4517-4520
54. Bernardo G., et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest. 20 (2002) 293-302
55. Lampson L.A. Basic principles of CNS immunology. In: Winn H.R. (Ed). Youman's Neurological Surgery. edn 5 (2003), Saunders 673-688
56. Lampson L.A. Immune regulation in the brain: lessons from autoimmunity, implications for brain tumor therapy. In: Ali-Osman F. (Ed). Human Brain Tumors (2004), Humana 175-205
57. Lampson L.A., and Tripp C.A. Antibody-secreting cells to deliver antibody against brain metastases. J. Clin. Oncol. 25 June 20 Suppl. (2007) 3047
58. Lampson L.A., et al. Exploiting the lacZ reporter gene for quantitative analysis of disseminated tumor growth within the brain: use of the lacZ gene product as a tumor antigen, for evaluation of antigenic modulation, and to facilitate image analysis of tumor growth in situ. Cancer Res. 53 (1993) 176-182